Table 3 Logistic Regression Prediction Models of Biochemical Failure for Research Cohort.
Characteristic | Baseline model | MRI model | ||||
|---|---|---|---|---|---|---|
Coefficient | OR (95%CI) | P value | Coefficient | OR (95%CI) | P value | |
Intercept | 1.106 | 3.023 (0.047–189.847) | 0.599 | 1.905 | 6.722e + 00 (6.394e− 02—6.726e + 02) | 0.417 |
Age at biopsy | − 0.036 | 0.965 (0.923–1.008) | 0.111 | − 0.035 | 9.568e− 01 (9.205e− 01—1.013e + 00) | 0.150 |
BMI | − 0.093 | 0.911 (0.816–1.015) | 0.095 | − 0.111 | 8.952e− 01 (7.931e− 01—1.007e + 00) | 0.068 |
PSA | 0.048 | 1.050 (1.015–1.089) | 0.007 | 0.047 | 1.048e + 00 (1.009e + 00—1.091e + 00) | 0.017 |
PSAD | 0.295 | 1.343 (0.413–4.159) | 0.606 | − 0.335 | 7.155e− 01 (1.953e− 01—2.519e + 00) | 0.599 |
Abnormal DRE | 0.482 | 1.619 (0.748–3.410) | 0.211 | 0.132 | 1.141e + 00 (4.725e− 01—2.635e + 00) | 0.762 |
Surgical technique | ||||||
RARP | NA | NA | NA | NA | NA | NA |
LRP | 0.261 | 1.298 (0.615–2.652) | 0.482 | 0.201 | 1.223e + 01 (5.402e− 01—2.680e + 00) | 0.620 |
ISUP grade | ||||||
GG1 | NA | NA | NA | NA | NA | NA |
GG2 | 0.521 | 1.683 (0.539–5.503) | 0.371 | 0.302 | 1.352e + 00 (3.946e− 01—4.817e + 00) | 0.631 |
GG3 | 1.182 | 3.260 (1.181 –9.999) | 0.028 | 0.778 | 2.177e + 00 (6.707e− 01—7.681e + 00) | 0.205 |
GG4 | 1.966 | 7.145 (2.791—20.969) | < 0.001 | 1.755 | 5.784e + 00 (1.990e + 00—1.937e + 01) | 0.002 |
GG5 | 4.097 | 60.133 (11.908—476.667) | < 0.001 | 3.682 | 3.974e + 01 (6.481e + 00—3.557e + 02) | < 0.001 |
Prostatic apex region | 0.568 | 1.764e + 00 (8.422e− 01—3.760e + 00) | 0.135 | |||
Basal region | 0.300 | 1.350e + 00 (4.589e− 01—3.745e + 00) | 0.573 | |||
Central peripheral zone | 0.912 | 2.490e + 00 (1.112e + 00—5.803e + 00) | 0.030 | |||
Central non− peripheral zone | 0.050 | 1.050e + 00 (4.116e− 01—2.615e + 00) | 0.917 | |||
Maximum diameter of index lesion | 0.474 | 1.607e + 00 (7.568e− 01—3.582e + 00) | 0.229 | |||
MRI EPE | − 1.740 | 1.755e− 01 (3.243e− 03—6.841e + 00) | 0.364 | |||
Seminal invasion | 0.315 | 1.370e + 00 (1.225e− 01—2.730e + 01) | 0.808 | |||
PI-RADS v2.1 category | ||||||
1 | NA | NA | NA | |||
2 | ||||||
3 | 4.404 | 8.175e + 01 (1.475e− 72—NA) | 0.875 | |||
4 | 4.878 | 1.313e + 02 (2.486e− 72—NA) | 0.861 | |||
5 | 4.846 | 1.273e + 02 (4.078e− 72—NA) | 0.862 | |||
Clinical stage, n (%) | ||||||
T1 | NA | NA | NA | |||
T2 | − 6.311 | 1.816e− 03 (NA—9.966e + 70) | 0.821 | |||
T3 | − 4.011 | 1.812e− 02 (NA—1.827e + 72) | 0.886 | |||
